Cargando…
Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer
Secondary lymphoid tissue chemokine (SLC/CCL21), one of the CC chemokines, exerts potent antitumor immunity by co-localizing T cells and dendritic cells at the tumor site and is currently tested against human solid tumors. Here, we investigated whether the combination of recombinant adenovirus encod...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462366/ https://www.ncbi.nlm.nih.gov/pubmed/25230206 http://dx.doi.org/10.1111/cas.12537 |
_version_ | 1782375641313705984 |
---|---|
author | Chen, Ping Luo, Shan Wen, Yan-Jun Li, Yu-Hua Li, Jiong Wang, Yong-Sheng Du, Li-Cheng Zhang, Ping Tang, Jiao Yang, Da-Bing Hu, Huo-Zhen Zhao, Xia Wei, Yu-Quan |
author_facet | Chen, Ping Luo, Shan Wen, Yan-Jun Li, Yu-Hua Li, Jiong Wang, Yong-Sheng Du, Li-Cheng Zhang, Ping Tang, Jiao Yang, Da-Bing Hu, Huo-Zhen Zhao, Xia Wei, Yu-Quan |
author_sort | Chen, Ping |
collection | PubMed |
description | Secondary lymphoid tissue chemokine (SLC/CCL21), one of the CC chemokines, exerts potent antitumor immunity by co-localizing T cells and dendritic cells at the tumor site and is currently tested against human solid tumors. Here, we investigated whether the combination of recombinant adenovirus encoding murine CCL21 (Ad-mCCL21) with low-dose paclitaxel would improve therapeutic efficacy against murine cancer. Immunocompetent mice bearing B16-F10 melanoma or 4T1 breast carcinoma were treated with either Ad-mCCL21, paclitaxel, or both agents together. Our results showed that Ad-mCCL21 + low-dose paclitaxel more effectively reduced the growth of tumors as compared with either treatment alone and significantly prolonged survival time of the tumor-bearing animals. These antitumor effects of the combined therapy were linked to altered cytokine network at the tumor site, enhanced apoptosis of tumor cells, and decreased formation of new vessels in tumors. Importantly, the combined therapy elicited a strong therapeutic antitumor immunity, which could be partly abrogated by the depletion of CD4(+) or CD8(+) T lymphocytes. Collectively, these preclinical evaluations may provide a combined strategy for antitumor immunity and should be considered for testing in clinical trials. |
format | Online Article Text |
id | pubmed-4462366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44623662015-10-05 Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer Chen, Ping Luo, Shan Wen, Yan-Jun Li, Yu-Hua Li, Jiong Wang, Yong-Sheng Du, Li-Cheng Zhang, Ping Tang, Jiao Yang, Da-Bing Hu, Huo-Zhen Zhao, Xia Wei, Yu-Quan Cancer Sci Original Articles Secondary lymphoid tissue chemokine (SLC/CCL21), one of the CC chemokines, exerts potent antitumor immunity by co-localizing T cells and dendritic cells at the tumor site and is currently tested against human solid tumors. Here, we investigated whether the combination of recombinant adenovirus encoding murine CCL21 (Ad-mCCL21) with low-dose paclitaxel would improve therapeutic efficacy against murine cancer. Immunocompetent mice bearing B16-F10 melanoma or 4T1 breast carcinoma were treated with either Ad-mCCL21, paclitaxel, or both agents together. Our results showed that Ad-mCCL21 + low-dose paclitaxel more effectively reduced the growth of tumors as compared with either treatment alone and significantly prolonged survival time of the tumor-bearing animals. These antitumor effects of the combined therapy were linked to altered cytokine network at the tumor site, enhanced apoptosis of tumor cells, and decreased formation of new vessels in tumors. Importantly, the combined therapy elicited a strong therapeutic antitumor immunity, which could be partly abrogated by the depletion of CD4(+) or CD8(+) T lymphocytes. Collectively, these preclinical evaluations may provide a combined strategy for antitumor immunity and should be considered for testing in clinical trials. Blackwell Publishing Ltd 2014-11 2014-11-20 /pmc/articles/PMC4462366/ /pubmed/25230206 http://dx.doi.org/10.1111/cas.12537 Text en © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Chen, Ping Luo, Shan Wen, Yan-Jun Li, Yu-Hua Li, Jiong Wang, Yong-Sheng Du, Li-Cheng Zhang, Ping Tang, Jiao Yang, Da-Bing Hu, Huo-Zhen Zhao, Xia Wei, Yu-Quan Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer |
title | Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer |
title_full | Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer |
title_fullStr | Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer |
title_full_unstemmed | Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer |
title_short | Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer |
title_sort | low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding ccl21 chemokine against murine cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462366/ https://www.ncbi.nlm.nih.gov/pubmed/25230206 http://dx.doi.org/10.1111/cas.12537 |
work_keys_str_mv | AT chenping lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT luoshan lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT wenyanjun lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT liyuhua lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT lijiong lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT wangyongsheng lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT dulicheng lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT zhangping lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT tangjiao lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT yangdabing lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT huhuozhen lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT zhaoxia lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer AT weiyuquan lowdosepaclitaxelimprovesthetherapeuticefficacyofrecombinantadenovirusencodingccl21chemokineagainstmurinecancer |